Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Wegovy Coverage with the New Cardiovascular Indication On March 8, 2024, the Food and Drug Administration (FDA) approved a new indication for the use of Wegovy (semaglutide) injections to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have cardiovascular disease and are either obese or overweight
Nat Biotechnol 43 , 455457 (2025)
Common side effects include nausea, vomiting, diarrhea, constipation, headaches and injection site reactions (redness, swelling, irritation)
We watch platelet counts closely to keep mom and baby safe
US$ 26.43
US$ 25.15
US$ 28.75
US$ 27.09
US$ 25.66
